Literature DB >> 33604513

Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection.

Jan Christoph Banck1, Niklas Mueller1,2, Sibylle Christiane Mellinghoff3,4, Martin Thelen5, Alessia Fraccaroli1, Viktoria Blumenberg1,2, Philipp Koehler3,4, Wolfgang Gerhard Kunz6, Martina Rudelius7, Florian Schrötzlmair8, Marion Subklewe1,2, Hans Anton Schlößer5,9, Johanna Tischer1, Oliver Andreas Cornely3,4,10, Lars Hartwin Lindner1, Michael von Bergwelt-Baildon1,11,12,13.   

Abstract

Entities:  

Year:  2021        PMID: 33604513      PMCID: PMC7886469          DOI: 10.1097/HS9.0000000000000530

Source DB:  PubMed          Journal:  Hemasphere        ISSN: 2572-9241


× No keyword cloud information.
  15 in total

Review 1.  Costimulation of T cells.

Authors:  L Bugeon; M J Dallman
Journal:  Am J Respir Crit Care Med       Date:  2000-10       Impact factor: 21.405

2.  Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy.

Authors:  Henning Zelba; Jonas Bochem; Graham Pawelec; Claus Garbe; Kilian Wistuba-Hamprecht; Benjamin Weide
Journal:  Cancer Immunol Immunother       Date:  2018-09-14       Impact factor: 6.968

Review 3.  A novel approach to candidemia? The potential role of checkpoint inhibition.

Authors:  Sibylle C Mellinghoff; Michael von Bergwelt-Baildon; Hans A Schößer; Oliver A Cornely
Journal:  Med Mycol       Date:  2019-02-01       Impact factor: 4.076

Review 4.  Role of PD-1 in regulating acute infections.

Authors:  Keturah E Brown; Gordon J Freeman; E John Wherry; Arlene H Sharpe
Journal:  Curr Opin Immunol       Date:  2010-04-27       Impact factor: 7.486

5.  Anti-PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice.

Authors:  Jonathan A Roussey; Steven P Viglianti; Seagal Teitz-Tennenbaum; Michal A Olszewski; John J Osterholzer
Journal:  J Immunol       Date:  2017-10-16       Impact factor: 5.422

6.  BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways.

Authors:  Peng Yue; Taylor Harper; Silvia M Bacot; Monica Chowdhury; Shiowjen Lee; Adovi Akue; Mark A Kukuruga; Tao Wang; Gerald M Feldman
Journal:  Oncoimmunology       Date:  2018-10-29       Impact factor: 8.110

7.  Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Authors:  A J Ullmann; J M Aguado; S Arikan-Akdagli; D W Denning; A H Groll; K Lagrou; C Lass-Flörl; R E Lewis; P Munoz; P E Verweij; A Warris; F Ader; M Akova; M C Arendrup; R A Barnes; C Beigelman-Aubry; S Blot; E Bouza; R J M Brüggemann; D Buchheidt; J Cadranel; E Castagnola; A Chakrabarti; M Cuenca-Estrella; G Dimopoulos; J Fortun; J-P Gangneux; J Garbino; W J Heinz; R Herbrecht; C P Heussel; C C Kibbler; N Klimko; B J Kullberg; C Lange; T Lehrnbecher; J Löffler; O Lortholary; J Maertens; O Marchetti; J F Meis; L Pagano; P Ribaud; M Richardson; E Roilides; M Ruhnke; M Sanguinetti; D C Sheppard; J Sinkó; A Skiada; M J G T Vehreschild; C Viscoli; O A Cornely
Journal:  Clin Microbiol Infect       Date:  2018-03-12       Impact factor: 8.067

Review 8.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

10.  Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.

Authors:  Katherine C Chang; Carey-Ann Burnham; Stephanie M Compton; David P Rasche; Richard J Mazuski; Jacquelyn S McDonough; Jacqueline Unsinger; Alan J Korman; Jonathan M Green; Richard S Hotchkiss
Journal:  Crit Care       Date:  2013-05-11       Impact factor: 9.097

View more
  3 in total

1.  Killing Two Birds With One Stone: Effective Control of Both Non-Small Cell Lung Cancer and Progressive Multifocal Leukoencephalopathy With Atezolizumab, A Case Report.

Authors:  Nicolas Lambert; Majdouline El Moussaoui; Caroline Ritacco; Martin Moïse; Astrid Paulus; Philippe Delvenne; Frédéric Baron; Bernard Sadzot; Pierre Maquet
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

2.  Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis.

Authors:  Alexandra Serris; Amani Ouedrani; Fabrice Uhel; Marianne Gazzano; Vincent Bedarida; Claire Rouzaud; Marie-Elisabeth Bougnoux; Jean-Herlé Raphalen; Sylvain Poirée; Olivier Lambotte; Guillaume Martin-Blondel; Fanny Lanternier
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

3.  Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis.

Authors:  Sebastian Wurster; Nathaniel D Albert; Uddalak Bharadwaj; Moses M Kasembeli; Jeffrey J Tarrand; Naval Daver; Dimitrios P Kontoyiannis
Journal:  Front Immunol       Date:  2022-02-18       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.